Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Clinical trial NCT02348216 · COMPLETED

Trial details

NCT number: NCT02348216
Sponsor: Kite, A Gilead Company
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B-Cell Lymphoma Transformed Follicular Lymphoma (TFL)Primary Mediastinal B-cell Lymphoma (PMBCL)High Grade B-cell Lymphoma (HGBCL)

Start date: 2015-04-21
Primary completion: 2023-07-27
Enrollment: 307

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.